TY - JOUR T1 - Acute myelitis after SARS-CoV-2 infection: a case report JF - medRxiv DO - 10.1101/2020.03.16.20035105 SP - 2020.03.16.20035105 AU - Kang Zhao AU - Jucun Huang AU - Dan Dai AU - Yuwei Feng AU - Liming Liu AU - Shuke Nie Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/18/2020.03.16.20035105.abstract N2 - We firstly reported a case of acute myelitis in a SARS-CoV-2-infected patient. A 66-year-old man with COVID-19 was admitted with acute flaccid paralysis of bilateral lower limbs and urinary and bowel incontinence. All serum microbiological studies were negative except for SARS-CoV-2 nucleic acid testing. Clinical findings could be ascribed to a post-infectious acute myelitis. He was receiving treatment with ganciclovir, lopinavir/ritonavir, moxifloxacin, dexamethasone, human immunoglobulin and mecobalamin. With a diagnosis of post-infectious acute myelitis and comprehensive treatment, paralysis of bilateral lower extremities ameliorated. After two times negative novel coronavirus RNA nasopharyngeal swabs tests, he was discharged and transferred to a designated hospital for isolation treatment and rehabilitation therapy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the second medical and health youth top talent project of Hubei Province (2019).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNo datasets were generated or analyzed for this study. ER -